COVID-19 may have the worlds attention, but Pfizer hasnt forgotten making investments elsewhere.

The New York pharma will invest 300 million ($350 million) to upgrade three Irish manufacturing sites in Grange Castle in Dublin, Newbridge in Kildare and Ringaskiddy in Cork, and add about 300 jobs over the next two to three years, the company said Monday.

The investments will be used to add new manufacturing capacity and lab space, as well as new technologies to ensure Pfizer is ready to support the next wave of medical innovations, it said.

Therapies requiring high volume injections are becoming more common across a broad range of therapeutic areas. This webinar will explore why adherence, safety and quality of life are important for patients, and how these key enablers contribute towards positive outcomes. We will also discuss existing challenges, such as drug development, regulatory, patient accessibility, and how device technologies can further improve patient outcomes. Register Today!

The three Irish sites manufacture drugs and vaccines in the areas of arthritis, inflammation, cancer, anti-infectives, hemophilia, pain and stroke, according to the company

The Ringaskiddy site, which wasPfizers first foothold in Ireland, will install adrug development operation to produce compounds for clinical trials. This is a very important development, as it expands Pfizers role in Ireland from the manufacture of already approved medicines into the support of an earlier phase of new medicine development, Paul Reid, Pfizer Irelands country manager said, as quoted by The Irish Times.

Pfizers currently in the spotlight for developing a COVID-19 vaccine with German partner BioNTech. The pairs mRNA candidate, BNT162b2, is among four programs currently in phase 3 efficacy trials in the U.S. Pfizer CEO Albert Bourla previously said the company could have preliminary efficacy data as early as October, but that didnt come through.

RELATED:Pfizer tags 3 U.S. manufacturing sites for possible COVID-19 vaccine launch

Right now, the firm doesnt intend to discuss any interim efficacy analysis until it has a conclusive readout from the data monitoring committee, Bourla told investors during a conference call last week. It will also accrue two-month safety data from half of the trial participants following the final dose of the vaccine, as the FDA requires. Based on our current trial enrollment and dosing pace, we estimate we will reach this milestone in the third week of November, he said.

In July, the company nabbed $1.95 billion from the U.S. government to supply 100 million doses of the vaccine upon emergency use authorization, with potentially an additional 500 million doses down the line. In the EU, where the BNT162b2 shot is under the European Medicines Agencys rolling review, Pfizer and BioNTech have penned an agreement to provide 200 million doses, with an option for 100 million more.

RELATED:Pfizer plans to ditch Perth sterile injectables manufacturing site by 2024, endangering 470 positions

To make those shots, Pfizer has designated three U.S. sites and a Belgium facility as its COVID-19 vaccine manufacturing centers. The Grange Castle operation in Ireland is helping with quality testing batches for the Belgium plant, according to The Irish Times. Bourla has said the company will have relevant manufacturing data before the safety readout to support its COVID-19 application in the U.S.

The Irish investment comes as Pfizer isplanning to exita sterile injectables manufacturing site in Perth, Australia. The company intends to wind down operations there by 2023 and move its functions to its Melbourne, Australia, facility and other plants overseas.

Visit link:
Pfizer to invest 300M, add 300 jobs to expand 3 Irish manufacturing sites - FiercePharma